What is it about?

Due to their potential for tissue engineering applications and ability to modulate the immune system and reduce inflammation, mesenchymal stem cells (MSCs) have been explored as a promising option for the treatment of chronic diseases and injuries. However, there are problems associated with the use of this type of cell that limit their applications. Several studies have been exploring the possibility to produce mesenchymal stem cells from pluripotent stem cells (PSCs). The aim of these studies is to generate MSCs with advantageous characteristics of both PSCs and MSCs. The results obtained in this study demonstrated that it is possible to induce the differentiation of both embryonic stem cells and induced pluripotent stem cells into cells with characteristics that highly resemble those from MSCs through the inhibition of the TGF-β pathway.

Featured Image

Why is it important?

The protocol described in this thesis proved to be an efficient system for generating MSC-like cells from human ESCs and iPSCs.


It is hoped that eventually the generation of mesenchymal stem cells from pluripotent stem cells will be achieved and iPSC/ESC-derived MSCs will be safe to use for future stem cell therapies.

Alessander Leyendecker Junior
Hospital Sirio-Libanes

Read the Original

This page is a summary of: TGF-β Inhibitor SB431542 Promotes the Differentiation of Induced Pluripotent Stem Cells and Embryonic Stem Cells into Mesenchymal-Like Cells, Stem Cells International, July 2018, Hindawi Publishing Corporation, DOI: 10.1155/2018/7878201.
You can read the full text:

Open access logo


The following have contributed to this page